Physician profile
Fran E Cogen
NPI 1083795694
$63,000.74
in general payments reported to CMS, 2019-2025
12 companies · $47K in 2025
The $47K reported for 2025 was more than what 97% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2022: $18.70 · 2023: $319 · 2024: $15K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Travel and Lodging: $5,327 · Consulting Fee: $5,030 · Food and Beverage: $3,272 · Long Term Medical Supply Or Device Loan: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,961.00 |
| Travel and Lodging | $5,326.90 |
| Consulting Fee | $5,030.00 |
| Food and Beverage | $3,272.07 |
| Long Term Medical Supply Or Device Loan | $274.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $61,506.19 | 2023-2025 | |
| Abbott Laboratories | $380.08 | 2024-2025 | Freestyle Insulinx, Freestyle Libre 3 |
| Sanofi US Services INC. | $305.44 | 2025 | |
| Beta Bionics, INC. | $220.44 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Dexcom, INC. | $209.62 | 2023-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $123.17 | 2025 | |
| Insulet Corporation | $77.71 | 2019-2024 | Omnipod |
| Novo Nordisk INC | $74.78 | 2019 | |
| Xeris Pharmaceuticals, INC. | $43.03 | 2024-2025 | Gvoke Hypopen |
| Sequel Med Tech, LLC | $23.46 | 2025 | Twiist |
| Becton, Dickinson and Company | $18.70 | 2022 | |
| Lilly USA, LLC | $18.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fran Cogen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.